We then analyzed the impact of stattic, a commonly used STAT3 inhibitor (it binds to the STAT3 SH2 domain and inhibits its activation [62]), on TME Stimulation-induced pro-metastatic activities in HR+/HER2− breast cancer cells. Here, STAT3 is linked to breast carcinoma.